Botulinum for Chronic Exertional Compartment Syndrome (Botox)
Comparison of Botulinum Toxin to Fasciotomy in Treatment of Chronic Exertional Compartment Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Illinois
-
Scott Air Force Base, Illinois, United States, 62225
- 375th Medical Group
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult ages 18-65
- Active duty military
- Unable to run 1.5 miles without producing symptoms, including aching, burning, numbness, tingling, or weakness in the affected limb
- Failed conservative treatment over a period of 2 months, including trial of rest, NSAIDs, icing, and stretching routine
- Meets standard of care clinical diagnostic intramuscular compartment pressure criteria for CECS, based on standardized IMP needle testing. See below for testing protocol and criteria.
Exclusion Criteria:
- Prior Botulinum toxin injections into the affected limb
- Prior compartment release of the affected limb
- Pregnant or becomes pregnant during the study
- Standard of care clinical exams indicating other more likely causes of leg pain
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Botulinum toxin injections
Botulinum toxin injections for chronic compartment syndrome
|
Botulinum toxin will be injected in the upper and lower portion of the affected area with a syringe
|
|
Active Comparator: surgical fasciotomy
surgical fasciotomy for chronic compartment syndrome
|
linear incisions will be made into the affected compartment releasing the underlying fascial layer, reducing the pressure of the compartment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lower Extremity Functional Index
Time Frame: 6 months
|
The Lower Extremity Functional Index measures the functional impairment of a patient with a lower extremity disorder.
It can be used to monitor the patient over time and to evaluate the effectiveness of an intervention.
Score ranges from 0 to 80. Lower scores indicate more functional impairment.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Brett Boyce, MD, Principal Investigator
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Disease Attributes
- Disease
- Musculoskeletal Diseases
- Muscular Diseases
- Chronic Disease
- Syndrome
- Compartment Syndromes
- Chronic Exertional Compartment Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Botulinum Toxins
Other Study ID Numbers
Other Study ID Numbers
- FWH20170037H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.